-+ 0.00%
-+ 0.00%
-+ 0.00%

Adlai Nortye Publishes Presentation on AN4035 Preclinical Cancer Research

PUBT·11/19/2026 13:09:31
Listen to the news
Adlai Nortye Publishes Presentation on AN4035 Preclinical Cancer Research
  • Adlai Nortye published a medical research presentation on preclinical results for AN4035, its CEACAM5-targeted antibody-drug conjugate carrying a pan-RAS(ON) inhibitor.
  • AN4035 combined with cetuximab achieved a 100% response rate across five patient-derived tumor models, versus 60% for AN4035 alone.
  • The combination showed no clear evidence of additive toxicity relative to AN4035 alone in monkeys; moderate skin ulceration remained an adverse finding.
  • Results support an ongoing Phase I trial evaluating AN4035 alone or with cetuximab in advanced solid tumors harboring RAS mutations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Group Ltd. published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.